"Also, I think you had a number of questions regarding iptacopan. And I believe, specifically, you were asking about our approach with iptacopan in PNH and combinations. As \u2013 and just for the folks online here, iptacopan is our first-in-class complement B \u2013 factor B inhibitor that acts upstream of C3 and C5. And as Alexion has their anti-C5. What we note is that we're targeting both intravascular hemolysis, which is the C5 inhibitors which target the intravascular, but we also target the C3."